Make Twice the Impact with Our Spring Match Challenge
Make Twice the Impact with Our Spring Match Challenge
Help us fight Alzheimer’s and deliver twice the help and hope during our Spring 2x Match Challenge. Your gift will advance research and help provide care and support for the millions affected by Alzheimer’s.
Donate NowAlzheimer’s Association Statement on Topline Results from the CELIA Phase 2 Clinical Trial of Tau-Targeting Therapy Diranersen (BIIB080)
“People living with Alzheimer’s and their families deserve more treatment options, and the pace of progress is accelerating,” said Joanne Pike, DrPH, Alzheimer’s Association president and CEO. “We look forward to seeing additional data and results when they are presented at the Alzheimer’s Association International Conference (AAIC®) in July 2026. Alzheimer’s is a complex disease, and people living with it deserve a research effort that pursues every promising lead.”
Tau is a protein that builds up in the brain in Alzheimer’s disease and contributes to memory loss and cognitive decline. The news comes as the Alzheimer’s Association, CurePSP and the Rainwater Charitable Foundation convene the global tau research community at the Tau Global Conference. The annual conference brings together leading scientists across academia, industry, government and philanthropy to drive transformative breakthroughs in tau research and treatment.
There is more to learn about what these results mean for people living with Alzheimer’s including the treatment’s benefit and safety profile. Phase 2 trials are designed to give researchers an early signal about whether a treatment may work and is safe enough to study in a larger group of people. Diranersen (BIIB080) received Fast Track designation from the U.S. Food and Drug Administration (FDA).
“Every trial — positive or negative — adds to what scientists understand about Alzheimer’s disease and other tauopathies and how to treat them,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead. “Tau is one of the hallmarks of these diseases, and scientists are pursuing it through several different approaches.”
The Alzheimer’s Association is deeply committed to advancing tau research, including an ongoing funding program between the Association and the Rainwater Charitable Foundation as well as our Part the Cloud clinical trials funding program to advance tau-based therapeutic approaches. The Association has more than $490 million in active and committed funding across more than 1,220 projects in 59 countries. Approximately 31% of that investment is related to tau.
We are in an era of unprecedented promise, with new treatments in various stages of development. The Alzheimer's treatment research pipeline spans many different approaches and targets — tau, inflammation, synaptic function, lifestyle interventions and more — in addition to anti-amyloid therapies. The Alzheimer’s Association envisions a future where there are many treatments available that address Alzheimer’s and other dementia in multiple ways, and can be combined into powerful combination therapies, most likely in conjunction with brain-healthy lifestyle guidance.
Diranersen (BIIB080) is an investigational therapy in development. It is not approved by the FDA and is not available outside of clinical trials. People interested in Alzheimer’s and dementia clinical trials can learn more through Alzheimer’s Association TrialMatch®.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
About the Alzheimer’s Association International Conference (AAIC)
AAIC is the world’s largest gathering of researchers from around the world focused on Alzheimer’s and other diseases that cause dementia. As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
- AAIC 2026: alz.org/aaic
- AAIC 2026 newsroom: alz.org/aaic/pressroom.asp